PACB — Pacific Biosciences Of California Cashflow Statement
0.000.00%
Last trade - 00:00- $387.11m
- $690.21m
- $154.01m
Annual cashflow statement for Pacific Biosciences Of California, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 29.4 | -181 | -314 | -307 | -310 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -13.6 | 135 | 94.6 | 98.2 | 103 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.76 | 21 | -54 | -59 | -40.6 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 19.5 | -111 | -263 | -259 | -206 |
| Capital Expenditures | -1.04 | -5.93 | -16.9 | -8.84 | -6.19 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -218 | -673 | 133 | 13.4 | 130 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -219 | -679 | 116 | 4.6 | 124 |
| Financing Cash Flow Items | 34 | -52.2 | — | -93.8 | -50.2 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 252 | 1,170 | 9.62 | 109 | -43 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 52 | 380 | -138 | -146 | -125 |